Thrombolysis in acute ischemic stoke: Critical analysis of current knowledge;Trombolys vid akut ischemisk stroke: Kritisk analys av aktuell kunskapsfront

Lakartidningen

Volumn 101, Issue 8, 2004, Pages 662-673

  Murray, Veronica ^a   Norrving, Bo ^b   Terént, Andreas ^c   Wester, Per ^d  

^a DANDERYD HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN; PLACEBO; PLASMIN; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DRUG INDICATION; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; HUMAN; META ANALYSIS; METHODOLOGY; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; STATISTICS; STROKE; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ACUTE DISEASE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HUMANS; INTRACRANIAL HEMORRHAGES; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SURVIVAL RATE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 1642418894     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Wardlaw JM, del Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 2003.
2. Molina CA, Montaner J, Abilleira S, Arenillas JF, Ribó M, Huertas R. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke. A case-control study. Stroke 2001;32:2821-7.
3. von Kummer R. Cerebral hemorrhage following thrombolysis in stroke. In: Wahlgren NG, Ahmed N, Hårdemark H-G, editors. Update on stroke therapy 2002-2003. Stockholm: Karolinska Stroke Update; 2003. pp.271-7.
4. Brott T. Individual patient data metaanalysis of rt-PA. Proceedings of the AHA 27thAnnual Meeting on Stroke; 2002, Feb 7-9; San Antonio, USA: American Heart Association; 2002.
5. The National Institute of Stroke and Neurological Disorders rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
6. Ingall TJ, O'Fallon WM, Louis TA, Hertzberg V, Goldfrank LR, Asplund K. Initial findings of the rt-PA acute stroke treatment review panel. Proceedings of the 12th European Stroke Conference; 2003 May 21-24; Valencia, Spain. Cerebrovasc Dis 2003;16 (suppl 4):125.
7. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
8. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-51.
9. Clark WM, Albers GW, Madden KP, Hamilton SA for the Thrombolytic Therapy in Acute Ischemic Stroke Study Investigators. The rtPA (Alteplase) 0-to 6-hour acute stroke trial, part A (A0276g). Results of a double-blind, placebo-controlled, multicenter study. Stroke 2000;31:811-6.
10. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S for the ATLANTIS Study Investigators. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. JAMA 1999;282:2019-26.
11. Warach S. Tissue viability thresholds in acute stroke. The 4-factor model. Stroke 2001;32:2460-1.
12. Adams HP, Adams RJ, Brott T, del Zoppo G, Furlan AJ, Goldstein LB, et al. Guidelines for the early management of patients with ischemic stroke. A scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003;34:1056-83.
13. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283:1151-8.
14. Hårdemark HG, Nordmark Ö, Terént A. Snabb trombolytisk behandling indicerad vid hotande hjärninfarkt. Läkartidningen 2002;99:4350-5.
15. Johnston S, Fung L, Gillum L, Smith W, Brass L, Lichtman J, et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at Academic centers. The influence of ethnicity. Stroke 2001;32:1061-8.
16. Sandercock P, Berge E, Dennis M, Hand P, Kwan J, Lewis S, et al. A systematic review of the effectiveness, cost-effectiveness and barriers to the implementation of thrombolytic and neuroprotective treatment in the NHS. Health Technology Assessment 2002;6:26. http://www.ncchta.org/
17. Wardlaw MJ, Lindley RI, Lewis S. Thrombolysis for acute ischemic stroke: still a treatment for the few by the few. West J Med 2002;176:198-9.
18. Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet 1993;342:891-4.
19. Trombolys vid stroke. Stockholm: Statens beredning för medicinsk utvärdering (SBU) Alert; 2003 http://www.sbu.se/Admin/index.asp.
20. Indredavik B. Skal alle (slag)pasienter ha samme behandling? B. Indredavik svarer. Tidskr Nor Laegeforen 2002;25:122.